Huateng Pharma Develops COVID-19 Drug Paxlovid & Ensitrelvir Intermediates

April 18, 2022

Now entering its third year, the COVID-19 virus is still one big health threat for the world's people. Today, we are yearning for the emergence of an effective drug that kills the COVID-19 virus in one fell swoop. The oral drug paxlovid and ensitrelvir could be game-changers. Huateng Pharma is a full-service Contract Development Manufacturing Organizations (CDMO) for pharmaceutical intermediates, including paxlovid and ensitrelvir intermediates, offering our customers innovative solutions to their bespoke projects, from the early clinical phase through to the commercial stage.

“Paxlovid and ensitrelvir are the potencial blockbuster drugs for COVID-19 treatment. And in response to this trend, our management decides to introduce a new product line, providing Paxlovid and ensitrelvir intermediates with the most reasonable price,” says the Marketing Chief of Huateng Pharma. ”Previously, we have already been a trust-wothy CDMO for pharmaceutical intermediates, offering custom synthesis and scale-up services for many years. We believe our relationship with our partners will be further strengthened after the launch of these popular pharmaceutical intermediates.”

On February 16, 2022, the data on Paxlovid previously published by Pfizer and submitted to the FDA were published in the New England Journal of Medicine (NEJM). This NEJM article published viral load data that Paxlovid reduced viral load by 0.868 log10 compared to controls for 5 days of treatment, which equates to a remarkable 7.38-fold reduction in viral load. This pivotal study (NCT04960202) enrolled 2,246 patients with COVID-19, 1,120 received Paxlovid and 1,126 received placebo. Interim analysis showed that 28 days after receiving treatment, Paxlovid reduced the risk of hospitalization and death by 89.1% (p<0.001). Applying the final results of the ITT analysis, Paxlovid reduced the risk of hospitalization and death by 88.9% (p<0.001).

Ensitrelvir (S-217622) showed promising activity (IC50 = 0.013 μM, EC50 = 0.37 μM) and oral bioavailability (stable metabolism, high oral absorption, low clearance). Also, it showed better inhibition against SARS-CoV, MERS-CoV, HCoV-OC43, HCoV-229E and other beta genus coronaviruses. The antiviral effect of S-217622 against SARS-CoV-2 Gamma strain was evaluated in mice. S-217622 treatment was given 12 hours after mice were infected with SARS-CoV-2 Gamma strain, and the results showed that S-217622 dose-dependently reduced the virus titer in the lungs of mice. S-217622 is currently undergoing clinical trial studies and is expected to be the first non-covalent non-peptide oral 3CL protease inhibitor for COVID-19 treatment.

About Huateng Pharma

Huateng Pharma is a global provider in contract development and manufacturing for intermediates.  With our focus on operational excellence, and the integration of manufacturing operations with EHS, quality assurance, quality control, regulatory, supply chain management and project management, we can manufacture, scale-up and supply high-quality intermediates and APIs from our China facility.

Contact Us

Address: Lugu Business Plaza E1, Yuelu District, Changsha City, Hunan Province, China
Manufacturing Base: Tongguan Kiln, Wangcheng district, Changsha, Hunan, China
Zip code: 410205
Telephone: +86 731 89916275
Fax: +86 0731-82251112-818